Citation

Akiyode O, Thomas T, Weaver S, Sahraoui S. Top. Geriatr. Rehabil. 2013; 29(3): 179-186.

Copyright

(Copyright © 2013, Lippincott Williams and Wilkins)

DOI

10.1097/TGR.0b013e31828aef5d

PMID

unavailable

Abstract

The prevalence of peripheral arterial disease is of concern in the older population because many of these individuals often have comorbid conditions (eg, hypertension, diabetes, dyslipidemia) commonly associated with the disease. The primary pharmacological management of these patientsÊ health is to reduce their risk for cardiovascular morbidity and mortality, followed by decreasing their intermittent claudication symptoms. The cardiovascular reduction management includes the use of antiplatelet medication such as aspirin or clopidogrel, statin therapy, and optimal control of hypertension, diabetes, and dyslipidemia. Lower extremity symptom improvement is managed pharmacologically with the use of smoking cessation regimens in patients with peripheral arterial disease who smoke and by cilostazol drug therapy. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Language: en

Keywords

human; suicide; aging; insomnia; depression; prevalence; insulin glargine; Geriatric; article; disease classification; amfebutamone; xerostomia; unclassified drug; sleep disorder; constipation; anticoagulant agent; acetylsalicylic acid; hydroxymethylglutaryl coenzyme A reductase inhibitor; placebo; drug efficacy; beta adrenergic receptor blocking agent; diarrhea; nausea; nicotine; geriatric patient; hypertension; diabetes mellitus; atorvastatin; antidiabetic agent; atenolol; dipeptidyl carboxypeptidase inhibitor; smoking cessation; pentoxifylline; metformin; tobacco dependence; mouth ulcer; dyslipidemia; drug induced headache; clopidogrel; blurred vision; anticoagulant therapy; exendin 4; varenicline; nicotine gum; nicotine replacement therapy; throat irritation; rhinorrhea; benazepril; cilostazol; nose irritation; intermittent claudication; antithrombocytic agent; commit; insulin glulisine; PAD; Pentoxifylline; Peripheral arterial disease; peripheral occlusive artery disease